SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Balis, F. M. Articles by Bleyer, W. A. Search for Related Content PubMed PubMed Citation Articles by Balis, F. M. Articles by Bleyer, W. A. Related Collections Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 92 No. 10 (November 15), 1998: pp. 3569-3577 Pharmacokinetics and Pharmacodynamics of Oral Methotrexate and Mercaptopurine in Children With Lower Risk Acute Lymphoblastic Leukemia: A Joint Children's Cancer Group and Pediatric Oncology Branch Study Frank M. Balis, John S. Holcenberg, David G. Poplack, Jeffrey Ge, Harland N. Sather, Robert F. Murphy, Matthew M. Ames, Mary J. Waskerwitz, David G. Tubergen, Solomon Zimm, Gerald S. Gilchrist, and W. Archie Bleyer From the Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD; and the Children's Cancer Group, Arcadia, CA. We prospectively assessed the pharmacokinetics of methotrexate, mercaptopurine, and erythrocyte thioguanine nucleotide levels in a homogenous population of children with lower risk acute lymphoblastic leukemia and correlated pharmacokinetic parameters with disease outcome. The maintenance therapy regimen included daily oral mercaptopurine (75 mg/m2) and weekly oral methotrexate (20 mg/m2). One hundred ninety-one methotrexate doses and 190 mercaptopurine doses were monitored in 89 patients. Plasma drug concentrations of both agents were highly variable. The area under the plasma concentration-time curve (AUC) of methotrexate ranged from 0.63 to 12 µmolh/L, and the AUC of mercaptopurine ranged from 0.11 to 8 µmolh/L. Drug dose, patient age, and duration of therapy did not account for the variability. Methotrexate AUC was significantly higher in girls than boys (P = .007). There was considerable intrapatient variability for both agents. Erythrocyte thioguanine nucleotide levels were also highly variable (range, 0 to 10 pmol/g Hgb) and did not correlate with mercaptopurine dose or AUC. A Cox regression analysis showed that mercaptopurine AUC was a marginally significant (P = .043) predictor of outcome, but a direct comparison of mercaptopurine AUC in the remission and relapsed patient groups failed to show a significant difference. Methotrexate and mercaptopurine plasma concentrations and erythrocyte thioguanine nucleotide levels were highly variable, but measurement of these pharmacokinetic parameters at the start of maintenance will not distinguish patients who are more likely to relapse. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: G. Zaza, M. Cheok, W. Yang, J. C. Panetta, C.-H. Pui, M. V. Relling, and W. E. Evans Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment Blood, September 1, 2005; 106(5): 1778 - 1785. [Abstract] [Full Text] [PDF] B. C. Bostrom, M. R. Sensel, H. N. Sather, P. S. Gaynon, M. K. La, K. Johnston, G. R. Erdmann, S. Gold, N. A. Heerema, R. J. Hutchinson, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group Blood, May 15, 2003; 101(10): 3809 - 3817. [Abstract] [Full Text] [PDF] P. Chiusolo, G. Reddiconto, I. Casorelli, L. Laurenti, F. Sora, L. Mele, L. Annino, G. Leone, and S. Sica Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate Ann. Onc., December 1, 2002; 13(12): 1915 - 1918. [Abstract] [Full Text] [PDF] C. Laverdiere, S. Chiasson, I. Costea, A. Moghrabi, and M. Krajinovic Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia Blood, November 15, 2002; 100(10): 3832 - 3834. [Abstract] [Full Text] [PDF] S. H. Cha, T. Sekine, J.-i. Fukushima, Y. Kanai, Y. Kobayashi, T. Goya, and H. Endou Identification and Characterization of Human Organic Anion Transporter 3 Expressing Predominantly in the Kidney Mol. Pharmacol., April 16, 2001; 59(5): 1277 - 1286. [Abstract] [Full Text] D. H. Mahoney Jr, J. J. Shuster, R. Nitschke, S. Lauer, C. P. Steuber, and B. Camitta Intensification With Intermediate-Dose Intravenous Methotrexate Is Effective Therapy for Children With Lower-Risk B-Precursor Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study J. Clin. Oncol., March 13, 2000; 18(6): 1285 - 1294. [Abstract] [Full Text] [PDF] C. A. Felix, B. J. Lange, and J. M. Chessells Pediatric Acute Lymphoblastic Leukemia: Challenges and Controversies in 2000 Hematology, January 1, 2000; 2000(1): 285 - 302. [Abstract] [Full Text] [PDF] F. M. Balis and P. C. Adamson Application of Pharmacogenetics to Optimization of Mercaptopurine Dosing J Natl Cancer Inst, December 1, 1999; 91(23): 1983 - 1985. [Full Text] [PDF] M. V. Relling, M. L. Hancock, G. K. Rivera, J. T. Sandlund, R. C. Ribeiro, E. Y. Krynetski, C.-H. Pui, and W. E. Evans Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-Methyltransferase Gene Locus J Natl Cancer Inst, December 1, 1999; 91(23): 2001 - 2008. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 1998 by American Society of Hematology         Online ISSN: 1528-0020